Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Mavefund
Dashboard
Eli Lilly and Company logo
LLY

Eli Lilly and Company

MaveScore 68 Medium model confidence
Last Price US$1,206.82 As of Jul 06, 2026
Market Cap US$1.1t Company size context
7D Performance -0.74% Past 7 days
1Y Performance 54.32% Past 12 months
Model Rating
Historical model output for research review

Fundamental data date

Mar 31, 2026

98 days old

Market price date

Jul 06, 2026

1 day old

Coverage

16/16

No missing model inputs

Data quality

Excellent

Current stored snapshot

Transparent research score

Why the model scores this stock

MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

MaveScore 68 Medium confidence

Stored data quality

Freshness and coverage checks

Latest stored fundamentals and price inputs are recent enough for normal research review.

16/16 Current stored snapshot

Quality

Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

28/35 Strong

Financial Strength

Financial strength rewards durable profitability, margins, and positive free cash flow.

18/25 Strong

Valuation Support

Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

3/15 Weak

Momentum

Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

9/15 Mixed

Shareholder Alignment

Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

10/10 Strong

Positive model output

  • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
  • Financial strength rewards durable profitability, margins, and positive free cash flow.
  • Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

Research risks to review

  • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
Dashboard Funda..tals Deep..lue Prediction Screener Map

Eli Lilly and Company Overview

Industry: Drug Manufacturers General

Sector: Healthcare

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, a Read More

Eli Lilly and Company is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

Eli Lilly and Company

Score

Reported Results

What the company reported, with filing details kept small.

Filed Apr 30, 2026

Quarterly result summary

Revenue was $8.7B (+125% YoY); EPS was $0.52 (reported).

Revenue $8.7B +125% YoY
EPS $0.52 reported
Net income $7.4B +168% YoY

What changed

  • Revenue +125% YoY to $8.7B; EPS reported to $0.52.
  • Net income +168% YoY to $7.4B.

Guidance / outlook

No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

Earnings release Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials
SEC filing 10-Q Apr 30, 2026 SEC filing 10-K Feb 12, 2026 Earnings release Earnings release Feb 04, 2026 SEC filing 10-Q Oct 30, 2025 Earnings release Earnings release Oct 30, 2025 SEC filing 10-Q Aug 07, 2025 Earnings release Earnings release Aug 07, 2025

Recent News



News Image
Eli Lilly Stock in Focus After Slashing Cost of Popular Drug
1 hour ago
News Image
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
2 hours ago
News Image
LLY Stock: Eli Lilly (LLY) Cuts Zepbound Starting Dose Prices, Matches Novo Nordisk’s Weight Loss Drug Discount
8 minutes ago

Earnings Per Share

Score 3.00/5
Eli Lilly and Company boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Drug Manufacturers General industry , Merck & Company Inc , Johnson & Johnson , Bristol-Myers Squibb Company are companies with high ratings.

Return on Equity

Score 4.80/5
Eli Lilly and Company stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

Sector Median 0%

In Drug Manufacturers General industry , Merck & Company Inc , Johnson & Johnson , Bristol-Myers Squibb Company are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

ROE

Company 0%

Sector Median 0%

Net Margin

Score 4.80/5
Eli Lilly and Company commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

Sector Median 0%

In Drug Manufacturers General industry , Merck & Company Inc , Johnson & Johnson , Bristol-Myers Squibb Company are companies with high ratings.

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

Sector Median 0%

0% 10.0% 20.0% 30.0% 40.0%

Net Margin

Company 0%

Sector Median 0%

Share Buyback

In Drug Manufacturers General industry , Merck & Company Inc , Johnson & Johnson , Bristol-Myers Squibb Company are companies with high ratings.

Leverage

Score 0.20/5
Eli Lilly and Company registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

Sector Median 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

Sector Median 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

Sector Median 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

Sector Median 0

In Drug Manufacturers General industry , Merck & Company Inc , Johnson & Johnson , Bristol-Myers Squibb Company are companies with high ratings.

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

Sector Median 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

Sector Median 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

Sector Median 0

0    10.0    20.0    30.0    40.0   

Leverage

Company 0

Sector Median 0

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Ticker Image

Eli Lilly and Company

US$1,206.82

US$1.1t

-0.74%

54.32%